Accueil › Cancer du poumon non à petites cellules › Tennessee
Essais cliniques pour Cancer du poumon non à petites cellules dans Tennessee
118 études pour Cancer du poumon non à petites cellules recherchent des participants dans Tennessee.
Villes dans Tennessee
Texte officiel de l'étude (anglais)
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
- Baptist Memorial Hospital and Cancer Center-Collierville, Collierville
- Regional Cancer Center at Johnson City Medical Center, Johnson City
- Ballad Health Cancer Care - Kingsport, Kingsport
- et 1 autres
Recrutement en coursPhase 3
Âges de 18 ans et plus · Tous sexes · Mis à jour le 2 oct. 2026 · NCT04267848A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
- Tennessee Oncology, PLLC - Chattanooga Downtown ( Site 0315), Chattanooga
- Thompson Cancer Survival Center ( Site 0168), Knoxville
- Elliston Place Medical Oncology & Hematology ( Site 0215), Nashville
Recrutement en coursPhase 3
Âges de 18 ans et plus · Tous sexes · Mis à jour le 2 oct. 2026 · NCT06623422Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor
- Tennessee Oncology - Chattanooga - Downtown, Chattanooga
- Tennessee Oncology - Chattanooga - GHCR Site I, Chattanooga
- Tennessee Oncology - Chattanooga - Memorial Plaza, Chattanooga
- et 6 autres
Recrutement en coursPhase 3
Âges de 18 ans et plus · Tous sexes · Mis à jour le 2 oct. 2026 · NCT06472245A Study of Targeted Post-Surgery Radiation Therapy for Non-Small Cell Lung Cancer With Remaining Lymph Node Cancer After Treatment
- Baptist Memorial Hospital and Cancer Center-Collierville, Collierville
- Baptist Memorial Hospital and Cancer Center-Memphis, Memphis
Recrutement en coursPhase 2
Âges de 18 ans et plus · Tous sexes · Mis à jour le 2 oct. 2026 · NCT07293247The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- Sarah Cannon Research Institute, Nashville
Recrutement en coursPhase 1/2
Âges de 12 ans et plus · Tous sexes · Mis à jour le 2 oct. 2026 · NCT04585750A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
- Sarah Cannon Research Institute, Nashville
- Tennessee Oncology PLLC, Nashville
Recrutement en coursPhase 1
Âges de 18 ans et plus · Tous sexes · Mis à jour le 2 oct. 2026 · NCT06465069Phase 1/2 Study of Intravenous Injection of STX-003 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab
- Sarah Cannon Research Institute, Nashville
Recrutement en coursPhase 1/2
Âges de 18 ans et plus · Tous sexes · Mis à jour le 2 oct. 2026 · NCT07751042A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer.
- Tennessee Oncology, Nashville
Recrutement en coursPhase 2/3
Âges de 18 ans et plus · Tous sexes · Mis à jour le 2 oct. 2026 · NCT07365319A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
- Tennessee Oncology, Nashville
Recrutement en coursPhase 1
Âges de 18 ans et plus · Tous sexes · Mis à jour le 2 oct. 2026 · NCT06270706Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
- Exelixis Clinical Site #3, Nashville
Recrutement en coursPhase 1
Âges de 18 ans et plus · Tous sexes · Mis à jour le 1 oct. 2026 · NCT05176483A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)
- The University of Tennessee Medical Center ( Site 3223), Knoxville
Recrutement en coursPhase 3
Âges de 18 ans et plus · Tous sexes · Mis à jour le 1 oct. 2026 · NCT07513376A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
- SCRI Oncology Partners, Nashville
Recrutement en coursPhase 2
Âges de 18 ans et plus · Tous sexes · Mis à jour le 1 oct. 2026 · NCT06172478A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
- Sarah Cannon Research Institute - Pharmacy, Nashville
- SCRI Oncology Partners, Nashville
Recrutement en coursPhase 1
Âges de 18 ans et plus · Tous sexes · Mis à jour le 1 oct. 2026 · NCT07090499A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
- Tennessee Cancer Specialists - Knoxville - Old Weisgarber Road /ID# 277891, Knoxville
- SCRI Oncology Partners /ID# 276959, Nashville
Recrutement en coursPhase 2/3
Âges de 18 ans et plus · Tous sexes · Mis à jour le 1 oct. 2026 · NCT07155187Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
- SCRI Oncology Partners, Nashville
Recrutement en coursPhase 1
Âges de 18 ans et plus · Tous sexes · Mis à jour le 1 oct. 2026 · NCT06625775Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
- Baptist Memorial Hospital and Cancer Center-Collierville, Collierville
- Baptist Memorial Hospital and Cancer Center-Memphis, Memphis
Recrutement en coursPhase 3
Âges de 18 ans et plus · Tous sexes · Mis à jour le 1 oct. 2026 · NCT06498635A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
- SCRI Oncology Partners, Nashville
- Tennessee Oncology, Nashville
Recrutement en coursPhase 3
Âges de 18 ans et plus · Tous sexes · Mis à jour le 30 sept. 2026 · NCT07361497Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
- SCRI Oncology Partners, Nashville
Recrutement en coursPhase 3
Âges de 18 ans et plus · Tous sexes · Mis à jour le 30 sept. 2026 · NCT06765109A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
- Research Site, Nashville
Recrutement en coursPhase 1
Âges de 18 ans et plus · Tous sexes · Mis à jour le 29 sept. 2026 · NCT05877599Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
- SCRI Oncology Partners - Tennessee, Nashville
Recrutement en coursPhase 3
Âges de 18 ans et plus · Tous sexes · Mis à jour le 29 sept. 2026 · NCT06881784A Study of PHN-012 in Patients With Advanced Solid Tumors
- PHN-012-001 Site, Nashville
Recrutement en coursPhase 1
Âges de 18 ans et plus · Tous sexes · Mis à jour le 29 sept. 2026 · NCT07127874A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
- Baptist Cancer Center, Bartlett
- Tennessee Oncology, PLLC - Chattanooga Downtown, Chattanooga
- Tennessee Oncology, PLLC - Chattanooga Med Park II, Chattanooga
- et 18 autres
Recrutement en coursPhase 3
Âges de 18 ans et plus · Tous sexes · Mis à jour le 28 sept. 2026 · NCT07144280A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
- University of Tennessee Medical Center Knoxville ( Site 0082), Knoxville
Recrutement en coursPhase 3
Âges de 18 ans et plus · Tous sexes · Mis à jour le 25 sept. 2026 · NCT06312137Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- Tennessee Oncology, PLLC - Chattanooga Downtown, Chattanooga
- Tennessee Oncology, PLLC - Chattanooga - Medical Park II, Chattanooga
- Tennessee Oncology, PLLC - Franklin, Franklin
- et 11 autres
Recrutement en coursPhase 3
Âges de 18 ans et plus · Tous sexes · Mis à jour le 25 sept. 2026 · NCT07222566A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
- Regional One Health, Memphis
- Sarah Cannon Research Institute, Nashville
- United States Oncology Regulatory Affairs Corporate Office, Nashville
Recrutement en coursPhase 3
Âges de 18 à 100 · Tous sexes · Mis à jour le 25 sept. 2026 · NCT05920356Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors
- Research Site, Nashville
Recrutement en coursPhase 1
Âges de 18 ans et plus · Tous sexes · Mis à jour le 25 sept. 2026 · NCT06218914Symbiotic-Lung-10: A Study to Learn About PF-08634404 Alone or in Combination in Early-stage or Locally Advanced NSCLC
- University of Tennessee Medical Center, Knoxville
Recrutement en coursPhase 2
Âges de 18 ans et plus · Tous sexes · Mis à jour le 25 sept. 2026 · NCT07489066Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
- Vanderbilt University Medical Center, Nashville
Recrutement en coursÉtude observationnelle
Âges de 18 ans et plus · Tous sexes · Mis à jour le 25 sept. 2026 · NCT04981119A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
- Tennessee Oncology - Chattanooga, Chattanooga
- Tennessee Cancer Specialists, Knoxville
- University of Tennessee, Knoxville
- et 2 autres
Recrutement en coursPhase 2
Âges de 18 ans et plus · Tous sexes · Mis à jour le 25 sept. 2026 · NCT06667076A Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
- University of Tennessee Medical Center, Knoxville
- Sarah Cannon Research Institute, Nashville
Recrutement en coursPhase 2
Âges de 18 ans et plus · Tous sexes · Mis à jour le 25 sept. 2026 · NCT07154290Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
- Tennessee Oncology Chattanooga, Chattanooga
- University of Tennessee Medical Center, Knoxville
- Sarah Cannon Research Institute, Nashville
- et 2 autres
Recrutement en coursPhase 3
Âges de 18 ans et plus · Tous sexes · Mis à jour le 24 sept. 2026 · NCT06890598Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
- Vanderbilt University Medical Center, Nashville
Recrutement en coursPhase 1/2
Âges de 18 ans et plus · Tous sexes · Mis à jour le 24 sept. 2026 · NCT06047379A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
- University of Tennessee Medical Center, Knoxville
Recrutement en coursPhase 1/2
Âges de 18 ans et plus · Tous sexes · Mis à jour le 23 sept. 2026 · NCT06618287Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer
- Research Site, Chattanooga
- Research Site, Memphis
- Research Site, Nashville
- et 1 autres
Recrutement en coursPhase 2
Âges de 18 à 95 · Tous sexes · Mis à jour le 23 sept. 2026 · NCT05061550Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer
- University of Tennessee Medical Center, Knoxville
- Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville
Recrutement en coursPhase 2/3
Âges de 18 ans et plus · Tous sexes · Mis à jour le 22 sept. 2026 · NCT06712316Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
- Sarah Cannon Research Institue, Nashville
Recrutement en coursPhase 1/2
Âges de 18 ans et plus · Tous sexes · Mis à jour le 22 sept. 2026 · NCT06128551A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
- SCRI Oncology Partners /ID# 270162, Nashville
Recrutement en coursPhase 2
Âges de 18 ans et plus · Tous sexes · Mis à jour le 22 sept. 2026 · NCT06568939Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
- Tennessee Oncology, Nashville
Recrutement en coursPhase 2/3
Âges de 18 ans et plus · Tous sexes · Mis à jour le 22 sept. 2026 · NCT07100080A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
- SCRI Oncology Partners, Nashville
- Local Institution - 0697, Nashville
Recrutement en coursPhase 3
Âges de 18 ans et plus · Tous sexes · Mis à jour le 22 sept. 2026 · NCT06875310Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
- Sarah Cannon - Tennessee Oncology, Nashville
Recrutement en coursPhase 1
Âges de 18 ans et plus · Tous sexes · Mis à jour le 21 sept. 2026 · NCT05983432Source : ClinicalTrials.gov, données récupérées le 5 oct. 2026. Chaque étude définit ses propres critères d'éligibilité ; l'équipe de l'étude décide qui peut y participer.